Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Wang, Lei ^a   Xiang, Shengyan ^a   Williams, Kendra A ^a   Dong, Huiqin ^a   Bai, Wenlong ^a,b   Nicosia, Santo V ^a,b   Khochbin, Saadi ^c   Bepler, Gerold ^d   Zhang, Xiaohong ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c INSTITUT ALBERT BONNIOT   (France)

^d KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATR PROTEIN; CHECKPOINT KINASE 1; CISPLATIN; HISTONE DEACETYLASE 6; PLATINUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CELL STRAIN A549; CELL STRAIN H292; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IC 50; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN DEPLETION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; COMET ASSAY; DNA DAMAGE; DOXORUBICIN; ETOPOSIDE; FEMALE; HISTONE DEACETYLASES; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84866032751     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0044265     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, et al. (2009) The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4: 792-801.
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, et al. (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360.
4. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, et al. (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721.
5. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, et al. (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589-2597.
6. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, et al. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7: 719-727.
7. Haberland M, Montgomery RL, Olson EN, (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42.
8. Yang XJ, Seto E, (2008) The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol 9: 206-218.
9. Verdel A, Khochbin S, (1999) Identification of a new family of higher eukaryotic histone deacetylases. Coordinate expression of differentiation-dependent chromatin modifiers. J Biol Chem 274: 2440-2445.
10. Grozinger CM, Hassig CA, Schreiber SL, (1999) Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci U S A 96: 4868-4873.
11. Seigneurin-Berny D, Verdel A, Curtet S, Lemercier C, Garin J, et al. (2001) Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol 21: 8035-8044.
12. Boyault C, Gilquin B, Zhang Y, Rybin V, Garman E, et al. (2006) HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 25: 3357-3366.
13. Hook SS, Orian A, Cowley SM, Eisenman RN, (2002) Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquitinating enzymes. Proc Natl Acad Sci U S A 99: 13425-13430.
14. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, et al. (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458.
15. Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, et al. (2007) HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27: 197-213.
16. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, et al. (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601-607.
17. Pandey UB, Nie Z, Batlevi Y, McCray BA, Ritson GP, et al. (2007) HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 447: 859-863.
18. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, et al. (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738.
19. Matthias P, Yoshida M, Khochbin S, (2008) HDAC6 a new cellular stress surveillance factor. Cell Cycle 7: 7-10.
20. Namdar M, Perez G, Ngo L, Marks PA, (2010) Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A 107: 20003-20008.
21. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, et al. (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92: 1300-1304.
22. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, et al. (2004) Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 59: 177-189.
23. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, et al. (2006) Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 281: 13548-13558.
24. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, et al. (2005) Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat 94: 11-16.
25. Huang BH, Laban M, Leung CH, Lee L, Lee CK, et al. (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12: 395-404.
26. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, et al. (2005) Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113: 264-268.
27. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, et al. (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455-463.
28. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, et al. (2004) HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 10: 6962-6968.
29. Ma X, Ezzeldin HH, Diasio RB, (2009) Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 69: 1911-1934.
30. Tan J, Cang S, Ma Y, Petrillo RL, Liu D, (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5.
31. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
32. Marks PA, Xu WS, (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107: 600-608.
33. Jafri SH, Glass J, Shi R, Zhang S, Prince M, et al. (2010) Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res 29: 87.
34. Andrews PA, Albright KD, (1992) Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. Cancer Res 52: 1895-1901.
35. Pozarowski P, Grabarek J, Darzynkiewicz Z (2004) Flow cytometry of apoptosis. Curr Protoc Cell Biol Chapter 18: Unit 18 18.
36. Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, et al. (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 5: 507-512.
37. Thiriet C, Hayes JJ, (2005) Chromatin in need of a fix: phosphorylation of H2AX connects chromatin to DNA repair. Mol Cell 18: 617-622.
38. Namdar M, Perez G, Ngo L, Marks PA, (2010) Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A 107: 20003-20008.
39. Olive PL, Banath JP, (2009) Kinetics of H2AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom 76: 79-90.
40. Yang J, Yu Y, Hamrick HE, Duerksen-Hughes PJ, (2003) ATM, ATR and DNA-PK: initiators of the cellular genotoxic stress responses. Carcinogenesis 24: 1571-1580.
41. Roos WP, Kaina B, (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12: 440-450.
42. Kim IA, No M, Lee JM, Shin JH, Oh JS, et al. (2009) Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: potential role of histone deacetylase 6. Radiother Oncol 92: 125-132.
43. Kanamori Y, Kigawa J, Minagawa Y, Irie T, Oishi T, et al. (1998) A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. Eur J Cancer 34: 1802-1806.
44. Kigawa J, Sato S, Shimada M, Kanamori Y, Itamochi H, et al. (2002) Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells. Gynecol Oncol 84: 210-215.
45. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J, et al. (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res 64: 356-362.
46. Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, et al. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677.
47. Khanna KK, Keating KE, Kozlov S, Scott S, Gatei M, et al. (1998) ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 20: 398-400.
48. She QB, Chen N, Dong Z, (2000) ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J Biol Chem 275: 20444-20449.
49. Persons DL, Yazlovitskaya EM, Pelling JC, (2000) Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 275: 35778-35785.
50. Kamemura K, Ito A, Shimazu T, Matsuyama A, Maeda S, et al. (2008) Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. Biochem Biophys Res Commun 374: 84-89.
51. Shieh SY, Ikeda M, Taya Y, Prives C, (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
52. Edmond V, Moysan E, Khochbin S, Matthias P, Brambilla C, et al. (2011) Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J 30: 510-523.
53. Long BH, Fairchild CR, (1994) Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 54: 4355-4361.
54. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, et al. (2010) Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 126: 743-755.
55. Zhou J, Oliveira P, Li X, Chen Z, Bepler G, (2010) Modulation of the ribonucleotide reductase-antimetabolite drug interaction in cancer cell lines. J Nucleic Acids 2010: 597098.
56. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, et al. (2008) The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68: 7561-7569.